De Luca Cinzia R, McCarthy Maria, Galvin Jane, Green Jessica L, Murphy Alexandra, Knight Sarah, Williams Jacqueline
Children's Cancer Centre, The Royal Children's Hospital, Melbourne, Australia.
Dev Neurorehabil. 2013 Jun;16(3):180-7. doi: 10.3109/17518423.2013.771221. Epub 2013 Mar 11.
Chemotherapy treatment for acute lymphoblastic leukaemia (ALL) may disrupt motor development, with suggestions that gross and fine motor deficits are different depending on time since treatment.
Thirty-seven participants aged between 2.5 to 5 years at the time of diagnosis were assessed using the Movement Assessment Battery for Children, 2nd Edition (MABC-2) and the Bruininks-Oseretsky Test of Motor Proficiency, 2nd Edition, Short Form (BOT-2 SF), and divided into groups (i.e., months-off-treatment): (1) 0-12, (2) 13-24, and (3) 25-60 for comparison.
MABC-2 and BOT-2 SF mean total scores fell within the average range. Twenty-six percent of the sample performed in the impaired range on the MABC-2. Group 2 had significantly lower Manual Dexterity scores than the normative population and lower BOT-2 SF scores than Group 1.
Most children treated for ALL display appropriate motor skills, yet around a quarter experience general motor difficulties. Time-off-treatment did not affect the prevalence of motor impairments on any measure.
急性淋巴细胞白血病（ALL）的化疗可能会干扰运动发育，有迹象表明，自治疗以来，粗大运动和精细运动缺陷因时间不同而有所差异。
对37名诊断时年龄在2.5至5岁之间的参与者，使用儿童运动评估量表第二版（MABC - 2）和布吕宁克斯 - 奥塞茨基运动能力测试第二版简版（BOT - 2 SF）进行评估，并根据治疗后间隔时间分组：（1）0 - 12个月，（2）13 - 24个月，（3）25 - 60个月，以进行比较。
MABC - 2和BOT - 2 SF的平均总分落在平均范围内。26%的样本在MABC - 2上的表现处于受损范围。第2组的手部灵活性得分显著低于正常人群，且BOT - 2 SF得分低于第1组。
大多数接受ALL治疗的儿童表现出适当的运动技能，但约四分之一的儿童存在一般运动困难。治疗后间隔时间对任何一项运动障碍指标的患病率均无影响。
